Method for generation of immunoglobulin sequences

Patent metadata

Field	Value
Publication number	US-9260508-B2
Application number	US-64328609-A
Country	US
Kind code	B2
Filing date	Dec 21, 2009
Priority date	Dec 19, 2008
Publication date	Feb 16, 2016
Grant date	Feb 16, 2016

Abstract

The present invention relates to a method for generating immunoglobulin sequences against cell-associated antigens, more particularly, antigens that are membrane-anchored. The invention also provides immunoglobulin sequences obtainable by the method of the invention. Specifically, the present invention relates to the generation of immunoglobulin sequences by use of DNA vaccination. More specifically, the present invention relates to generation of immunoglobulin sequences in camelids, preferably directed against cell-associated antigens, in particular antigens with multiple transmembrane spanning domains, including GPCRs and ion channels, by DNA vaccination. Furthermore, the present invention relates to said immunoglobulin sequences against cell-associated antigens, more particularly, antigens that are membrane-anchored, such as e.g. GPCRs and ion channels, more preferably ion channels.

First claim

The invention claimed is:

1. Method for the generation of immunoglobulin sequences that can bind to and/or have affinity for a transmembrane antigen in its natural conformation comprising the steps of:
a) genetic vaccination of a camelid with an isolated nucleic acid encoding said transmembrane antigen or a domain or specific part of said transmembrane antigen, wherein said transmembrane antigen is selected from G-protein coupled receptors (GPCRs) and ion channels;
b) boosting the camelid with natural or transfected cells expressing the transmembrane antigen in its natural conformation, wherein said transmembrane antigen is selected from GPCRs and ion channels; and
c) screening a set, collection or library of immunoglobulin sequences derived from said camelid for immunoglobulin sequences that can bind to and/or have affinity for said transmembrane antigen in its natural conformation, wherein said transmembrane antigen is selected from GPCRs and ion channels.

2. The method according to claim 1 , wherein the camelid is an alpaca or llama.

3. The method according to claim 1 , wherein said immunoglobulin sequences are light chain variable domain sequences, or heavy chain variable domain sequences.

4. The method according to claim 3 , wherein the immunoglobulin sequences are heavy chain variable domain sequences that are derived from a conventional four-chain antibody or heavy chain variable domain sequences that are derived from a heavy chain antibody.

5. The method according to claim 1 , wherein the immunoglobulin sequences are domain antibodies, single domain antibodies, Nanobodies, VHH sequences, humanized immunoglobulin sequence or camelized immunoglobulin sequences.

6. The method according to claim 5 , wherein the immunoglobulin sequences are Nanobodies.

7. The method according to claim 1 , wherein vaccination is performed by a needle-free jet injection, by a ballistic method, by needle-mediated injections, by topical application or by any DNA administration method followed by in vivo electroporation.

8. The method according to claim 1 , wherein vaccination is performed by intradermal, intramuscular or subcutaneous administration of DNA.

9. The method according to claim 1 , wherein the set, collection or library of immunoglobulin sequences is obtained from the blood, lymph node, spleen, bone marrow or any tissue harbouring cells encoding these immunoglobulin sequences of said non-human mammal.

10. The method according to claim 1 , wherein said transmembrane antigen is expressed on any cell which allows expressing of the transmembrane antigen in its native conformation.

11. The method according to claim 1 , wherein said transmembrane antigen is selected from CXCR7, CXCR4 or/and P2X7.

12. The method according to claim 1 , wherein the set, collection or library of immunoglobulin sequences is expressed on a set, collection or sample of cells or viruses and said set, collection or sample of cells is screened for cells that express an immunoglobulin sequence that can bind to and/or have affinity for said transmembrane antigen.

13. The method according to claim 12 , wherein a nucleic acid sequence that encodes the immunoglobulin sequence that can bind to and/or has affinity for said transmembrane antigen is purified and/or isolated from the cell or virus, followed by expression of said immunoglobulin sequence.

14. The method according to claim 1 , wherein the set, collection or library of immunoglobulin sequences is encoded by a set, collection or library of nucleic acid sequences and said set, collection or library of nucleic acid sequences is screened for nucleic acid sequences that encode an immunoglobulin sequence that can bind to and/or has affinity for said transmembrane antigen.

15. The method according to claim 14 , wherein the nucleic acid sequences that encode an immunoglobulin sequence that can bind to and/or has affinity for said transmembrane antigen are purified and/or isolated, followed by expressing said immunoglobulin sequence.

16. The method according to claim 1 , wherein the immunoglobulin sequence that can bind to and/or has affinity for said transmembrane antigen is purified and/or is isolated.

17. The method according to claim 10 , wherein said cell is selected from Cho, Cos7, Hek293, camel derived cells, dromedary derived cells, Llama derived cells or Alpaca derived cells.

18. The method according to claim 1 , wherein the immunoglobulin sequences are VHH, camelized VH or humanized VHH.

Assignees

• Laeremans Toon
• Stortelers Catelijne
• Nolte Friedrich
• Gonzalez Pajuelo Maria
• Assunção Joana
• Rompaey Philippe Van
• Ablynx Nv

Inventors

• Laeremans Toon
• Stortelers Catelijne
• Nolte Friedrich
• Gonzalez Pajuelo Maria
• Assunção Joana
• Rompaey Philippe Van

Classifications

• C07K2317/569

  Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody® · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K16/2866

  against receptors for cytokines, lymphokines, interferons · CPC title

• C07K2317/567

  Framework region [FR] · CPC title

• C07K16/28 Primary

  against receptors, cell surface antigens or cell surface determinants · CPC title